662 related articles for article (PubMed ID: 36126785)
1. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery.
Zimmermann CM; Baldassi D; Chan K; Adams NBP; Neumann A; Porras-Gonzalez DL; Wei X; Kneidinger N; Stoleriu MG; Burgstaller G; Witzigmann D; Luciani P; Merkel OM
J Control Release; 2022 Nov; 351():137-150. PubMed ID: 36126785
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effects of storage conditions on spray-dried siRNA-LNPs before and after subsequent drying.
Zimmermann CM; Deßloch L; Jürgens DC; Luciani P; Merkel OM
Eur J Pharm Biopharm; 2023 Dec; 193():218-226. PubMed ID: 37956785
[TBL] [Abstract][Full Text] [Related]
3. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles.
Keil TWM; Feldmann DP; Costabile G; Zhong Q; da Rocha S; Merkel OM
Eur J Pharm Biopharm; 2019 Oct; 143():61-69. PubMed ID: 31445157
[TBL] [Abstract][Full Text] [Related]
4. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.
Meenach SA; Vogt FG; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
Int J Nanomedicine; 2013; 8():275-93. PubMed ID: 23355776
[TBL] [Abstract][Full Text] [Related]
5. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA.
Jensen DK; Jensen LB; Koocheki S; Bengtson L; Cun D; Nielsen HM; Foged C
J Control Release; 2012 Jan; 157(1):141-8. PubMed ID: 21864597
[TBL] [Abstract][Full Text] [Related]
6. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung.
Sham JO; Zhang Y; Finlay WH; Roa WH; Löbenberg R
Int J Pharm; 2004 Jan; 269(2):457-67. PubMed ID: 14706257
[TBL] [Abstract][Full Text] [Related]
7. Spray drying lactose from organic solvent suspensions for aerosol delivery to the lungs.
Ke WR; Chang RYK; Kwok PCL; Chen D; Chan HK
Int J Pharm; 2020 Dec; 591():119984. PubMed ID: 33069893
[TBL] [Abstract][Full Text] [Related]
8. Spray-Dried and Spray-Freeze-Dried Powder Formulations of an Anti-Interleukin-4Rα Antibody for Pulmonary Delivery.
Pan HW; Seow HC; Lo JCK; Guo J; Zhu L; Leung SWS; Zhang C; Lam JKW
Pharm Res; 2022 Sep; 39(9):2291-2304. PubMed ID: 35879500
[TBL] [Abstract][Full Text] [Related]
9. Development of spray-freeze-dried siRNA/PEI powder for inhalation with high aerosol performance and strong pulmonary gene silencing activity.
Okuda T; Morishita M; Mizutani K; Shibayama A; Okazaki M; Okamoto H
J Control Release; 2018 Jun; 279():99-113. PubMed ID: 29627404
[TBL] [Abstract][Full Text] [Related]
10. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
[TBL] [Abstract][Full Text] [Related]
11. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
[TBL] [Abstract][Full Text] [Related]
12. Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer.
Chow MYT; Qiu Y; Lo FFK; Lin HHS; Chan HK; Kwok PCL; Lam JKW
Int J Pharm; 2017 Sep; 530(1-2):40-52. PubMed ID: 28720537
[TBL] [Abstract][Full Text] [Related]
13. Development of a Spray-Dried Formulation of Peptide-DNA Nanoparticles into a Dry Powder for Pulmonary Delivery Using Factorial Design.
Munir M; Kett VL; Dunne NJ; McCarthy HO
Pharm Res; 2022 Jun; 39(6):1215-1232. PubMed ID: 35441318
[TBL] [Abstract][Full Text] [Related]
14. Effect of lipid composition on RNA-Lipid nanoparticle properties and their sensitivity to thin-film freezing and drying.
AboulFotouh K; Southard B; Dao HM; Xu H; Moon C; Williams Iii RO; Cui Z
Int J Pharm; 2024 Jan; 650():123688. PubMed ID: 38070660
[TBL] [Abstract][Full Text] [Related]
15. Aerosolizable siRNA-encapsulated solid lipid nanoparticles prepared by thin-film freeze-drying for potential pulmonary delivery.
Wang JL; Hanafy MS; Xu H; Leal J; Zhai Y; Ghosh D; Williams Iii RO; David Charles Smyth H; Cui Z
Int J Pharm; 2021 Mar; 596():120215. PubMed ID: 33486021
[TBL] [Abstract][Full Text] [Related]
16. Optical photothermal infrared spectroscopy for nanochemical analysis of pharmaceutical dry powder aerosols.
Khanal D; Kim J; Zhang J; Ke WR; Holl MMB; Chan HK
Int J Pharm; 2023 Feb; 632():122563. PubMed ID: 36586629
[TBL] [Abstract][Full Text] [Related]
17. Effect of thermal and shear stresses in the spray drying process on the stability of siRNA dry powders.
Wu J; Wu L; Wan F; Rantanen J; Cun D; Yang M
Int J Pharm; 2019 Jul; 566():32-39. PubMed ID: 31077763
[TBL] [Abstract][Full Text] [Related]
18. High siRNA loading powder for inhalation prepared by co-spray drying with human serum albumin.
Chow MYT; Qiu Y; Liao Q; Kwok PCL; Chow SF; Chan HK; Lam JKW
Int J Pharm; 2019 Dec; 572():118818. PubMed ID: 31678379
[TBL] [Abstract][Full Text] [Related]
19. Understanding the impact of mannitol on physical stability and aerosolization of spray-dried protein powders for inhalation.
Arte KS; Tower CW; Mutukuri TT; Chen Y; Patel SM; Munson EJ; Tony Zhou Q
Int J Pharm; 2024 Jan; 650():123698. PubMed ID: 38081559
[TBL] [Abstract][Full Text] [Related]
20. Spray dried lipid nanoparticle formulations enable intratracheal delivery of mRNA.
Friis KP; Gracin S; Oag S; Leijon A; Sand E; Lindberg B; Lázaro-Ibáñez E; Lindqvist J; Whitehead KA; Bak A
J Control Release; 2023 Nov; 363():389-401. PubMed ID: 37741463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
